Dr. Chamoun is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11100 Euclid Ave
Cleveland, OH 44106
Education & Training
Lebanese University School of MedicineClass of 2011
Certifications & Licensure
OH State Medical License 2018 - 2021
Publications & Presentations
PubMed
- 12 citationsOral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.Sangmin Lee, Sanjay Mohan, Jessica Knupp, Kamal Chamoun, Adrienne de Jonge
Journal of Hematology & Oncology. 2022-08-03 - 1 citationsEffect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Anal...Michael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, Joost S P Vermaat, Nagesh Kalakonda
Clinical Lymphoma, Myeloma & Leukemia. 2022-07-01 - 2 citationsThe Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.Josée M Zijlstra, George Follows, Rene-Olivier Casasnovas, Joost S P Vermaat, Nagesh Kalakonda
Cancers. 2022-02-04
Press Mentions
American Society of Clinical Oncology, May 31-June 4June 7th, 2019
Location and Insurance Matter When It Comes to Survival in Multiple MyelomaJune 2nd, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
